Comparing Treatments for Bleeding in Trauma Patients
This study is looking at how well two treatments, Prothrombin Complex Concentrate (PCC) and recombinant activated factor VIIa (rFVIIa), work in adult trauma patients who need a lot of blood transfusions. Researchers want to see if these treatments, used alone or together, can reduce serious blood clots (thromboembolic events). They will also compare how these treatments affect survival, how much blood is needed, and how long patients stay in the hospital or ICU. You might be able to join if you are an adult (18 or older) with severe trauma who needs a massive blood transfusion. The study will look at these outcomes 28 days after treatment.
- Study design
- This is an observational study, meaning researchers will watch and collect information from a small group of 4 participants. It is not specified if participants will be assigned to different treatment groups.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Researchers will check for blood clots (thromboembolic events) 28 days after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Comparative Outcomes of PCC and Recombinant Activated Factor VIIa in Trauma-Associated Massive Transfusion
At a glance
Conditions
Where it's being run
2 sites across 1 statesStudy leadership
- AYTEN SARAÇOĞLU, Prof,MD · STUDY_DIRECTOR · Florida University Jacksonville
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- thromboembolic events28 days
Number of Participants with venous thrombosis, pulmonary embolism, ischemic stroke, mesenteric ischemia